Distinguished in Hepatitis B

Yuemin M. Nan

No. 139, Ziqiang Road, 
Shijiazhuang, CN 
Distinguished in Hepatitis B
No. 139, Ziqiang Road, 
Shijiazhuang, CN 
OverviewLocationsClinical Research

Overview

Yuemin Nan practices in Shijiazhuang, China. Nan is rated as a Distinguished expert by MediFind in the treatment of Hepatitis B. Their top areas of expertise are Cirrhosis, Hepatitis, Hepatitis B, and Non-Alcoholic Fatty Liver Disease.

Their clinical research consists of co-authoring 145 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 35 articles and participated in 1 clinical trial in the study of Hepatitis B.

Locations

No. 139, Ziqiang Road, Shijiazhuang, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Study Phase: Phase 3
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2021
Intervention Type: Drug
Study Drug: Entecavir
Study Phase: Phase 4
View 1 Less Clinical Trial

145 Total Publications

4EBP1 phosphorylation mediates TGF-β1-induced hepatic fibrosis and upregulates HIF-1α expression.
4EBP1 phosphorylation mediates TGF-β1-induced hepatic fibrosis and upregulates HIF-1α expression.
Journal: iScience
Published: June 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Nan's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile